financetom
Business
financetom
/
Business
/
UBS Says The Canadian Dollar Story Is "Mainly" A US Dollar Story
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UBS Says The Canadian Dollar Story Is "Mainly" A US Dollar Story
Aug 2, 2024 4:42 AM

07:16 AM EDT, 08/02/2024 (MT Newswires) -- Canada's economic ties with the United States aren't as helpful as in the past, given they first and foremost revolve around manufacturing sectors rather than services, which is what has driven the latest bout of US growth, said UBS.

In addition, Canada lacks big-ticket fiscal support packages and with Canadian consumers more exposed to high interest rates via mortgages, the resulting economic slowdown has inevitably been more pronounced, wrote the bank in a note to clients. As a result, growth has slowed, though inflation has also come down.

This led the Bank of Canada (BoC) to embark on rate cuts-rightly so, in the view of UBS.

UBS also expects the Canadian central bank to keep easing policy further at upcoming meetings. The bank asks if this actually matters for the Canadian dollar (CAD or loonie).

Canadian rates have repriced quite markedly to account for this policy pivot, stated UBS. Surprisingly, this has had little effect on the Canadian dollar.

Instead, news from across the border has influenced the currency much more significantly, according to the bank. Investors have very carefully weighed any data print from the US and Federal Reserve commentary.

UBS thinks relative rates have a tad further to run, but what it believes will likely push USDCAD lower will come from the US side. The US dollar (USD) should weaken once the Fed embarks on its easing cycle, which the bank thinks should start in September.

Lastly, UBS noted that positioning has become fairly extreme in the CAD, with large shorts built by the speculative community, leaving USDCAD vulnerable to a sharper correction if they are squeezed. Indeed, the bank believes the pair will trade lower over time.

Rate differentials will likely continue to be CAD-negative in the

short run, but once broader USD weakness takes hold later in the year, USDCAD should depreciate, according to UBS.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Keurig Dr Pepper Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing
Keurig Dr Pepper Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing
Mar 8, 2024
10:05 AM EST, 03/08/2024 (MT Newswires) -- Peter Harf, Director, on March 05, 2024, executed a purchase for 171,821 shares in Keurig Dr Pepper ( KDP ) for $4,999,991. Following the Form 4 filing with the SEC, Harf has control over a total of 3,802,205 shares of the company, with 182,605 shares held directly and 3,619,600 controlled indirectly. SEC Filing:...
Rivian surges as new launch R2 SUV attracts strong early orders
Rivian surges as new launch R2 SUV attracts strong early orders
Mar 8, 2024
March 8 (Reuters) - Rivian jumped 7% on Friday as its cheaper R2 SUV racked up tens of thousands of reservations within hours of its launch, fueling optimism that the electric-vehicle maker could expand in the mass-market segment. Unveiled on Thursday, the smaller R2 SUV, which will start at $45,000, has attracted more than 68,000 reservations, CEO RJ Scaringe said...
--Hudson Pacific Properties Reinstates Dividend at $0.05 per Share; Payable March 28 to Holders of Record on March 18
--Hudson Pacific Properties Reinstates Dividend at $0.05 per Share; Payable March 28 to Holders of Record on March 18
Mar 8, 2024
10:26 AM EST, 03/08/2024 (MT Newswires) -- Price: 7.05, Change: +0.37, Percent Change: +5.54 ...
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise
Mar 8, 2024
10:25 AM EST, 03/08/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Friday it dosed the first subjects in a phase 1/2a study of its experimental ARO-DM1 treatment of type 1 myotonic dystrophy, the most common adult-onset muscular dystrophy. The study will evaluate single and multiple ascending doses of ARO-DM1 in up to 48 patients, the company said. Patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved